FDA Advisory Committee Unanimously Votes Against Expanding Pfizer's Prostate Cancer Drug Combo on May 22, 2025 Advisory Committees enzalutamide expansion Inhibitor Labels (device) Malignant neoplasm of prostate mCRPC PARP1 gene Pfizer talazoparib Talzenna unanimous vote United States Food and Drug Administration +